Molecular Profiles of Prostate Cancer: To Treat or Not to Treat

被引：14
作者：
Sternberg, Itay A. [1 ]
Vela, Ian [2 ,3 ]
Scardino, Peter T. [4 ,5 ]
机构：
[1] Meir Med Ctr, Dept Urol, IL-4428164 Kefar Sava, Israel
[2] Queensland Univ Technol, Princess Alexandra Hosp, Dept Urol, Brisbane, Qld 4001, Australia
[3] Queensland Univ Technol, Australian Prostate Canc Res Ctr, Brisbane, Qld 4001, Australia
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10065 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
active surveillance; risk stratification; genomic classifier; ACTIVE SURVEILLANCE COHORT; RADICAL PROSTATECTOMY; RISK STRATIFICATION; GENOMIC CLASSIFIER; 10-YEAR PROBABILITY; FOLLOW-UP; BIOPSY; RECURRENCE; PROGRESSION; VALIDATION;
D O I：
10.1146/annurev-med-060413-112226
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
A major dilemma in the selection of treatment for men with prostate cancer is the difficulty in accurately characterizing the risk posed by the cancer. This uncertainty has led physicians to recommend aggressive therapy for most men diagnosed with prostate cancer and has led to concerns about the benefits of screening and the adverse consequences of excessive treatment. Genomic analyses of prostate cancer reveal distinct patterns of alterations in the genomic landscape of the disease that show promise for improved prediction of prognosis and better medical decision making. Several molecular profiles are now commercially available and are being used to inform medical decisions. This article describes the clinical tests available for distinguishing aggressive from nonaggressive prostate cancer, reviews the new genomic tests, and discusses their advantages and limitations and the evidence for their utility in various clinical settings.
引用
收藏
页码：119 / 135
页数：17
相关论文
共 64 条
  • [1] Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer
    Abrahamsson, PA
    Anderson, J
    Boccon-Gibod, L
    Schulman, C
    Studer, UE
    Wirth, M
    [J]. EUROPEAN UROLOGY, 2005, 48 (06) : 900 - 905
  • [2] American Cancer Society, 2015, EST DEATHS 4 MAJ CAN
  • [3] Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery
    Badani, Ketan K.
    Thompson, Darby J.
    Brown, Gordon
    Holmes, Daniel
    Kella, Naveen
    Albala, David
    Singh, Amar
    Buerki, Christine
    Davicioni, Elai
    Hornberger, John
    [J]. BJU INTERNATIONAL, 2015, 115 (03) : 419 - 429
  • [4] Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance
    Berglund, Ryan K.
    Masterson, Timothy A.
    Vora, Kinjal C.
    Eggener, Scott E.
    Eastham, James A.
    Guillonneau, Bertrand D.
    [J]. JOURNAL OF UROLOGY, 2008, 180 (05) : 1964 - 1967
  • [5] Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
    Bill-Axelson, Anna
    Holmberg, Lars
    Garmo, Hans
    Rider, Jennifer R.
    Taari, Kimmo
    Busch, Christer
    Nordling, Stig
    Haggman, Michael
    Andersson, Swen-Olof
    Spangberg, Anders
    Andren, Ove
    Palmgren, Juni
    Steineck, Gunnar
    Adami, Hans-Olov
    Johansson, Jan-Erik
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (10) : 932 - 942
  • [6] Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy
    Bishoff, Jay T.
    Freedland, Stephen J.
    Gerber, Leah
    Tennstedt, Pierre
    Reid, Julia
    Welbourn, William
    Graefen, Markus
    Sangale, Zaina
    Tikishvili, Eliso
    Park, Jimmy
    Younus, Adib
    Gutin, Alexander
    Lanchbury, Jerry S.
    Sauter, Guido
    Brawer, Michael
    Stone, Steven
    Schlomm, Thorsten
    [J]. JOURNAL OF UROLOGY, 2014, 192 (02) : 409 - 414
  • [7] Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
    Blume-Jensen, Peter
    Berman, David M.
    Rimm, David L.
    Shipitsin, Michail
    Putzi, Mathew
    Nifong, Thomas P.
    Small, Clayton
    Choudhury, Sibgat
    Capela, Teresa
    Coupal, Louis
    Ernst, Christina
    Hurley, Aeron
    Kaprelyants, Alex
    Chang, Hua
    Giladi, Eldar
    Nardone, Julie
    Dunyak, James
    Loda, Massimo
    Klein, Eric A.
    Magi-Galluzzi, Cristina
    Latour, Mathieu
    Epstein, Jonathan I.
    Kantoff, Philip
    Saad, Fred
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2591 - 2600
  • [8] Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    Bolla, Michel
    van Poppel, Hein
    Tombal, Bertrand
    Vekemans, Kris
    Da Pozzo, Luigi
    de Reijke, Theo M.
    Verbaeys, Antony
    Bosset, Jean-Francois
    van Velthoven, Roland
    Colombel, Marc
    van de Beek, Cees
    Verhagen, Paul
    van den Bergh, Alphonsus
    Sternberg, Cora
    Gasser, Thomas
    van Tienhoven, Geertjan
    Scalliet, Pierre
    Haustermans, Karin
    Collette, Laurence
    [J]. LANCET, 2012, 380 (9858) : 2018 - 2027
  • [9] Recent advances in image-guided targeted prostate biopsy
    Brown, Anna M.
    Elbuluk, Osama
    Mertan, Francesca
    Sankineni, Sandeep
    Margolis, Daniel J.
    Wood, Bradford J.
    Pinto, Peter A.
    Choyke, Peter L.
    Turkbey, Baris
    [J]. ABDOMINAL IMAGING, 2015, 40 (06): : 1788 - 1799
  • [10] Copy Number Alterations in Prostate Tumors and Disease Aggressiveness
    Cheng, Iona
    Levin, Albert M.
    Tai, Yu Chuan
    Plummer, Sarah
    Chen, Gary K.
    Neslund-Dudas, Christine
    Casey, Graham
    Rybicki, Benjamin A.
    Witte, John S.
    [J]. GENES CHROMOSOMES & CANCER, 2012, 51 (01) : 66 - 76
1234567